RNA interference-mediated FANCF silencing sensitizes OVCAR3 ovarian cancer cells to adriamycin through increased adriamycin-induced apoptosis dependent on JNK activation Corrigendum in /10.3892/or.2022.8327

He,Miao; Sun,Hai-Gang; Hao,Jun-Ying; Li,Yan-Lin; Yu,Jian-Kun; Yan,Yuan-Yuan; Zhao,Lin; Li,Na; Wang,Yan; Bai,Xue-Feng; Yu,Zhao-Jin; Zheng,Zhi-Hong; Mi,Xiao-Yi; Wang,En-Hua; Wei,Min-Jie

doi:10.3892/or.2013.2295

RNA interference-mediated FANCF silencing sensitizes OVCAR3 ovarian cancer cells to adriamycin through increased adriamycin-induced apoptosis dependent on JNK activation

Corrigendum in: /10.3892/or.2022.8327

Authors:
- Miao He
- Hai-Gang Sun
- Jun-Ying Hao
- Yan-Lin Li
- Jian-Kun Yu
- Yuan-Yuan Yan
- Lin Zhao
- Na Li
- Yan Wang
- Xue-Feng Bai
- Zhao-Jin Yu
- Zhi-Hong Zheng
- Xiao-Yi Mi
- En-Hua Wang
- Min-Jie Wei
View Affiliations

Affiliations: Department of Pharmacology, China Medical University, Heping, Shenyang, Liaoning 110001, P.R. China, Institute of Pathology and Pathophysiology, China Medical University, Heping, Shenyang, Liaoning 110001, P.R. China
Published online on: February 21, 2013 https://doi.org/10.3892/or.2013.2295
Pages: 1721-1729
Copyright: © He et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In the present study, we downregulated FANCF expression by small interfering RNA (siRNA) in OVCAR ovarian cancer cells to address the effects of decreased FANCF expression on the function of the Fanconi anemia (FA)/breast cancer susceptibility gene (BRCA) pathway. Furthermore, we investigated whether this method increases the sensitivity of OVCAR3 cells to adriamycin (ADM) and the possible mechanism(s). We found that silencing of FANCF inactivated the FA/BRCA pathway by decreasing the monoubiquitination and focus formation of FANCD2 and reduced the function of the FA/BRCA pathway, resulting in the inhibition of cell proliferation, increased cell apoptosis and DNA damage in OVCAR3 cells. Moreover, we observed that silencing of FANCF enhanced the antiproliferative effect of ADM in OVCAR3 cells and increased ADM intracellular accumulation consequently sensitizing OVCAR3 cells to ADM. Furthermore, silencing of FANCF increased cell apoptosis of OVCAR3 cells which was caused by decreased mitochondrial membrane potential (MMP)-induced DNA damage, activated Jun N-terminal kinase (JNK), increased release of cytochrome c, increased expression of cleaved caspase-3 and poly(ADP-ribose) polymerase (PARP) dependent on JNK activation following treatment of ADM. Collectively, we confirm that silencing of FANCF sensitizes OVCAR3 ovarian cancer cells to ADM, suggesting that FANCF may serve as a potential target for therapeutic strategies in the treatment of ovarian cancer.

View Figures

View References

1	Permuth-Wey J and Sellers TA: Epidemiology of ovarian cancer. Methods Mol Biol. 472:413–437. 2009. View Article : Google Scholar
2	Marchetti C, Pisano C, Facchini G, et al: First-line treatment of advanced ovarian cancer: current research and perspectives. Expert Rev Anticancer Ther. 10:47–60. 2010. View Article : Google Scholar : PubMed/NCBI
3	Orth K, Hung J, Gazdar A, et al: Genetic instability in human ovarian cancer cell lines. Proc Natl Acad Sci USA. 91:9495–9499. 1994. View Article : Google Scholar : PubMed/NCBI
4	Matsuo K, Eno ML, Im DD, et al: Clinical relevance of extent of extreme drug resistance in epithelial ovarian carcinoma. Gynecol Oncol. 116:61–65. 2010. View Article : Google Scholar : PubMed/NCBI
5	Jacquemont C, Simon JA, D’Andrea AD and Taniguchi T: Non-specific chemical inhibition of the Fanconi anemia pathway sensitizes cancer cells to cisplatin. Mol Cancer. 11:262012. View Article : Google Scholar : PubMed/NCBI
6	Hucl T and Gallmeier E: DNA repair: exploiting the Fanconi anemia pathway as a potential therapeutic target. Physiol Res. 60:453–465. 2011.PubMed/NCBI
7	Su X and Huang J: The Fanconi anemia pathway and DNA interstrand cross-link repair. Protein Cell. 2:704–711. 2011. View Article : Google Scholar : PubMed/NCBI
8	Leveille F, Blom E, Medhurst AL, et al: The Fanconi anemia gene product FANCF is a flexible adaptor protein. J Biol Chem. 279:39421–39430. 2004. View Article : Google Scholar : PubMed/NCBI
9	Kowal P, Gurtan AM, Stuckert P, et al: Structural determinants of human FANCF protein that function in the assembly of a DNA damage signaling complex. J Biol Chem. 282:2047–2055. 2007. View Article : Google Scholar : PubMed/NCBI
10	Taniguchi T, Tischkowitz M, Ameziane N, et al: Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med. 9:568–574. 2003. View Article : Google Scholar : PubMed/NCBI
11	Lim SL, Smith P, Syed N, et al: Promoter hypermethylation of FANCF and outcome in advanced ovarian cancer. Br J Cancer. 98:1452–1456. 2008. View Article : Google Scholar : PubMed/NCBI
12	Wang Z, Li M, Lu S, et al: Promoter hypermethylation of FANCF plays an important role in the occurrence of ovarian cancer through disrupting Fanconi anemia-BRCA pathway. Cancer Biol Ther. 5:256–260. 2006. View Article : Google Scholar : PubMed/NCBI
13	Chen Q, Van der Sluis PC, Boulware D, et al: The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells. Blood. 106:698–705. 2005. View Article : Google Scholar : PubMed/NCBI
14	Chen CC, Taniguchi T and D’Andrea A: The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents. J Mol Med. 85:497–509. 2007. View Article : Google Scholar : PubMed/NCBI
15	Valerio MR, Tagliaferrri P, Raspagliesi F, et al: A phase II study of pegylated liposomal doxorubicin oxaliplatin and cyclophosphamide as second-line treatment in relapsed ovarian carcinoma. Int J Gynecol Cancer. 16:79–85. 2006. View Article : Google Scholar : PubMed/NCBI
16	Sehouli J, Camara O, Schmidt M, et al: Pegylated liposomal doxorubicin (CAELYX) in patients with advanced ovarian cancer: results of a German multicenter observational study. Cancer Chemother Pharmacol. 64:585–591. 2009. View Article : Google Scholar : PubMed/NCBI
17	Lei T, Srinivasan S, Tang Y, et al: Comparing cellular uptake and cytotoxicity of targeted drug carriers in cancer cell lines with different drug resistance mechanisms. Nanomedicine. 7:324–332. 2011. View Article : Google Scholar : PubMed/NCBI
18	Singh NP, McCoy MT, Tice RR and Schneider EL: A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res. 175:184–191. 1988. View Article : Google Scholar
19	Klaude M, Eriksson S, Nygren J and Ahnström G: The comet assay: mechanisms and technical considerations. Mutat Res. 363:89–96. 1996. View Article : Google Scholar : PubMed/NCBI
20	Gordon SM, Alon N and Buchwald M: FANCC, FANCE, and FANCD2 form a ternary complex essential to the integrity of the Fanconi anemia DNA damage response pathway. J Biol Chem. 280:36118–36125. 2005. View Article : Google Scholar : PubMed/NCBI
21	Li Y, Liu Y, Fu Y, et al: The triggering of apoptosis in macrophages by pristine graphene through the MAPK and TGF-beta signaling pathways. Biomaterials. 33:402–411. 2012. View Article : Google Scholar : PubMed/NCBI
22	Ji C, Yang B, Yang YL, et al: Exogenous cell-permeable C6 ceramide sensitizes multiple cancer cell lines to doxorubicin-induced apoptosis by promoting AMPK activation and mTORC1 inhibition. Oncogene. 29:6557–6568. 2010. View Article : Google Scholar : PubMed/NCBI
23	D’Andrea AD: The Fanconi anemia/BRCA signaling pathway: disruption in cisplatin-sensitive ovarian cancers. Cell Cycle. 2:290–292. 2003.PubMed/NCBI
24	Kim H and D’Andrea AD: Regulation of DNA cross-link repair by the Fanconi anemia/BRCA pathway. Genes Dev. 26:1393–1408. 2012. View Article : Google Scholar : PubMed/NCBI
25	Garcia-Higuera I, Taniguchi T, Ganesan S, et al: Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol Cell. 7:249–262. 2001. View Article : Google Scholar : PubMed/NCBI
26	Bogliolo M, Lyakhovich A, Callén E, Castellà M, et al: Histone H2AX and Fanconi anemia FANCD2 function in the same pathway to maintain chromosome stability. EMBO J. 26:1340–1351. 2007. View Article : Google Scholar : PubMed/NCBI
27	Joenje H and Patel KJ: The emerging genetic and molecular basis of Fanconi anaemia. Nat Rev Genet. 2:446–457. 2001. View Article : Google Scholar : PubMed/NCBI
28	Burden DA and Osheroff N: Mechanism of action of topoisomerase II and drugs targeted to the enzyme. Biochim Biophys Acta. 1400:139–154. 1998. View Article : Google Scholar : PubMed/NCBI
29	Clementi ME, Giardina B, Di Stasio E, et al: Doxorubicin-derived metabolites induce release of cytochrome C and inhibition of respiration on cardiac isolated mitochondria. Anticancer Res. 23:2445–2450. 2003.PubMed/NCBI
30	Green PS and Leeuwenburgh C: Mitochondrial dysfunction is an early indicator of doxorubicin-induced apoptosis. Biochim Biophys Acta. 1588:94–101. 2002. View Article : Google Scholar : PubMed/NCBI
31	Bar-Joseph H, Ben-Aharon I, Rizel S, et al: Doxorubicin-induced apoptosis in germinal vesicle (GV) oocytes. Reprod Toxicol. 30:566–572. 2010. View Article : Google Scholar : PubMed/NCBI
32	Naci D, El Azreq MA, Chetoui N, et al: α2β1 integrin promotes chemoresistance against doxorubicin in cancer cells through extracellular signal-regulated kinase (ERK). J Biol Chem. 287:17065–17076. 2012.
33	Aroui S, Mili D, Brahim S, et al: Doxorubicin coupled to penetratin promotes apoptosis in CHO cells by a mechanism involving c-Jun NH2-terminal kinase. Biochem Biophys Res Commun. 396:908–914. 2010. View Article : Google Scholar : PubMed/NCBI
34	Budihardjo I, Oliver H, Lutter M, et al: Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol. 15:269–290. 1999. View Article : Google Scholar : PubMed/NCBI
35	Velagapudi C, Bhandari BS, Abboud-Werner S, et al: The tuberin/mTOR pathway promotes apoptosis of tubular epithelial cells in diabetes. J Am Soc Nephrol. 22:262–273. 2011. View Article : Google Scholar : PubMed/NCBI
36	Li M, Wang AJ and Xu JX: Redox state of cytochrome c regulates cellular ROS and caspase cascade in permeablized cell model. Protein Pept Lett. 15:200–205. 2008. View Article : Google Scholar : PubMed/NCBI